Allergy Therapeutics' Phase III of Grass MATA MPL meets goal

Allergy Therapeutics (AIM: AGY) today said that a trial evaluating the efficacy of its subcutaneous allergen-specific immunotherapy candidate has met its primary goal, with the news sending the UK biotech’s shares up 20.8% to 1.80 pence.

The pivotal G306 Phase III trial of Grass MATA MPL, the firm’s short-course subcutaneous allergen-specific immunotherapy (SCIT) candidate, aims to address the cause of symptoms of allergic rhinoconjunctivitis due to grass pollen.

The adaptive G306 study design, endorsed by regulators, allowed an interim analysis to determine whether a second cohort would be required. The trial met its primary endpoint demonstrating statistically-significant superiority of Grass MATA MPL compared to placebo (p ≤0.0024, one-sided) in the CSMS during the peak pollen season, and the study was stopped for success. Top line analysis is expected to be available in mid-December. This will include treatment effect data and secondary endpoint analysis.